Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5948242 | 1.00 | CHRM2 (0.48) | CHRM2CHRM1CHRM3SIGMAR1ALDH1A1 | |
| SCHEMBL4076574 | 0.80 | CHRM2 (0.58) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4076571 | 0.80 | CHRM2 (0.58) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4466104 | 0.76 | CHRM3 (0.43) | CHRM2CHRM1CHRM3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9196506 | 0.72 | KDM4E (0.51) | CHRM2CHRM1CHRM3SIGMAR1ALDH1A1 | |
| SCHEMBL3912068 | 0.71 | CHRM2 (0.54) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3908289 | 0.71 | CHRM2 (0.54) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3920032 | 0.71 | CHRM2 (0.54) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5948406 | 0.71 | CHRM2 (0.56) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3913264 | 0.71 | CHRM2 (0.53) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 5/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.